Goldenberg G J, Brandes L J, Lau W H, Miller A B, Wall C, Ho J H
Cancer Treat Rep. 1985 Jul-Aug;69(7-8):761-7.
A prospectively randomized, double-blind clinical trial was conducted to evaluate the effect of immunotherapy with transfer factor (TF) as an adjunct to radiotherapy of patients with stage III nasopharyngeal carcinoma (NPC). The TF was derived from normal young adults with a proven history of infectious mononucleosis and from normal blood donors with elevated antiviral capsid antigen antibody activity. TF prepared in this fashion was previously shown to convert the leukocytes of patients with NPC to a reactive state in vitro and when administered to NPC patients in vivo was associated with apparent slowing of tumor growth, marked lymphocytic infiltration of the tumor, and reconstitution of delayed cutaneous hypersensitivity reactions. From 1974 to 1977, 100 patients with NPC were entered in the study; one-half of the patients were treated with radiotherapy alone and one-half received radiotherapy and an 18-month course of TF immunotherapy. The patients were followed for at least 5 years. No significant difference in disease-free survival or survival was noted between the two groups of patients. The use of this particular preparation and dose schedule of TF in patients with NPC with regional disease was devoid of any anti-tumor activity.
开展了一项前瞻性随机双盲临床试验，以评估用转移因子（TF）进行免疫治疗作为III期鼻咽癌（NPC）患者放射治疗辅助手段的效果。TF取自有传染性单核细胞增多症确诊病史的正常年轻人以及抗病毒衣壳抗原抗体活性升高的正常献血者。先前已表明，以这种方式制备的TF在体外可使NPC患者的白细胞转变为反应状态，并且在体内给予NPC患者时，与肿瘤生长明显减缓、肿瘤有明显淋巴细胞浸润以及迟发型皮肤过敏反应重建有关。1974年至1977年，100例NPC患者进入该研究；其中一半患者仅接受放射治疗，另一半患者接受放射治疗及为期18个月的TF免疫治疗疗程。对患者进行了至少5年的随访。两组患者在无病生存期或总生存期方面均未观察到显著差异。在患有局部疾病的NPC患者中使用这种特定的TF制剂和剂量方案没有任何抗肿瘤活性。
